Artemis and its role in cancer

IF 5 2区医学 Q2 Medicine

Translational Oncology Pub Date : 2024-11-08 DOI:10.1016/j.tranon.2024.102165

Armen Parsyan , Vasudeva Bhat , Harjot Athwal , Emily A. Goebel , Alison L Allan

{"title":"Artemis and its role in cancer","authors":"Armen Parsyan , Vasudeva Bhat , Harjot Athwal , Emily A. Goebel , Alison L Allan","doi":"10.1016/j.tranon.2024.102165","DOIUrl":null,"url":null,"abstract":"<div><div>Artemis is a key nuclease involved in the non-homologous end joining repair pathway upon DNA double-stranded breaks and during V(D)J recombination. It participates in various cellular processes and cooperates with various proteins involved in tumorigenesis. Its hereditary mutations lead to several pathological conditions, such as severe combined immunodeficiency with radiation sensitivity. Recent studies suggest that Artemis deregulation plays an important role in cancer and is associated with poorer oncologic outcomes and resistance to treatment including radiotherapy, chemotherapy and targeted therapeutics. Artemis emerges as an attractive candidate for cancer prognosis and treatment. Its role in modulating sensitivity to ionizing radiation and DNA-damaging agents makes it an appealing target for drug development. Various existing drugs and novel compounds have been described to inhibit Artemis activity. This review synthesizes the up-to-date information regarding Artemis function, its role in different malignancies and its clinical utility as a potential biomarker and therapeutic target in Oncology.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"51 ","pages":"Article 102165"},"PeriodicalIF":5.0000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523324002912","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Artemis is a key nuclease involved in the non-homologous end joining repair pathway upon DNA double-stranded breaks and during V(D)J recombination. It participates in various cellular processes and cooperates with various proteins involved in tumorigenesis. Its hereditary mutations lead to several pathological conditions, such as severe combined immunodeficiency with radiation sensitivity. Recent studies suggest that Artemis deregulation plays an important role in cancer and is associated with poorer oncologic outcomes and resistance to treatment including radiotherapy, chemotherapy and targeted therapeutics. Artemis emerges as an attractive candidate for cancer prognosis and treatment. Its role in modulating sensitivity to ionizing radiation and DNA-damaging agents makes it an appealing target for drug development. Various existing drugs and novel compounds have been described to inhibit Artemis activity. This review synthesizes the up-to-date information regarding Artemis function, its role in different malignancies and its clinical utility as a potential biomarker and therapeutic target in Oncology.

Abstract Image

查看原文本刊更多论文

阿尔忒弥斯及其在癌症中的作用

Artemis 是一种关键的核酸酶，在 DNA 双链断裂和 V(D)J 重组过程中参与非同源末端连接修复途径。它参与多种细胞过程，并与多种参与肿瘤发生的蛋白质合作。它的遗传突变会导致多种病症，如对辐射敏感的严重联合免疫缺陷症。最近的研究表明，Artemis 的失调在癌症中发挥着重要作用，并与较差的肿瘤治疗效果以及对放疗、化疗和靶向治疗等疗法的耐药性有关。Artemis 成为癌症预后和治疗的一个有吸引力的候选对象。它在调节对电离辐射和 DNA 损伤剂的敏感性方面的作用，使其成为一个有吸引力的药物开发靶点。已有多种现有药物和新型化合物被描述为能抑制 Artemis 的活性。这篇综述综述了有关Artemis功能的最新信息、它在不同恶性肿瘤中的作用及其作为肿瘤学潜在生物标记物和治疗靶点的临床实用性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.